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Abstract
Introduction: To elucidate in polymyalgia rheumatica (PMR) the role of tumor necrosis factor (TNF) a and the
therapeutic potential of blockade with soluble TNF-a receptor, we carried out the first randomized controlled trial
with etanercept in PMR.
Methods: Twenty newly diagnosed, glucocorticoid (GC) naïve patients with PMR and 20 matched non-PMR control
subjects completed the trial. Subjects were randomized in a 1:1 ratio to monotherapy with etanercept (25 mg s.c.
biweekly) or placebo (saline) for 14 days. Study outcomes were assessed at baseline and after 14 days. The primary
outcome was the change in PMR activity score (PMR-AS). Secondary outcomes were: changes in erythrocyte
sedimentation rate (ESR) and plasma levels of TNF-a and interleukin (IL) 6; patients’ functional status (health
assessment questionnaire) and cumulative tramadol intake during the trial.
Results: At baseline, plasma TNF-a was higher in patients than in controls (P < 0.05). The concentration always
increased with etanercept treatment (P < 0.05). In patients, etanercept decreased PMR-AS by 24% (P = 0.011),
reflecting significant improvements in shoulder mobility, physician’s global assessment and C-reactive protein, and
insignificant (P > 0.05) improvements in duration of morning stiffness and patient’s assessment of pain. In parallel,
ESR and IL-6 were reduced (P < 0.05). Placebo treatment did not change PMR-AS, ESR and IL-6 (P > 0.05).
Functional status did not change and tramadol intake did not differ between patient groups. In controls, no
changes occurred in both groups.
Conclusions: Etanercept monotherapy ameliorates disease activity in GC naïve patients with PMR. However, the
effect is modest, indicating a minor role of TNF-a in PMR.
Trial registration: ClinicalTrials.gov (NCT00524381).
Introduction
Polymyalgia rheumatica (PMR) is the most common
chronic inflammatory disease in the elderly [1]. Clini-
cally, it is characterized by pain in the neck and lower
back as well as proximal extremity complaints, including
tender, aching, and stiff muscles. Patients feel fatigued
and their level of physical activity is reduced [1]. These
symptoms are accompanied by elevated erythrocyte
sedimentation rate (ESR) and increased blood levels of
C-reactive protein (CRP) [1].
The knowledge of the etiology and pathophysiology of
PMR is modest. The prevailing view is that PMR reflects
inflammatory processes in synovial membranes in joints,
bursae, and tendons [1-4]. Several studies have found
elevated blood levels of various proinflammatory cyto-
kines in PMR [5]. Recently, we showed that levels of
proinflammatory cytokines, including IL-6 and TNF-a,
w h i c hb o t hp o t e n t l yi n d u c e the expression of acute
phase reactants [6] and promote nociception [7,8], are
increased in the interstitium of affected muscles [9].
The only effective treatment is medium-dose gluco-
corticoids (GC), which abolish symptoms within a few
days [10]. However, because long-term treatment is
necessary, serious adverse effects, including type 2 dia-
betes, hypertension, and osteoporosis, are frequent [11].
In patients with rheumatoid arthritis (RA), another
chronic inflammatory disease and an important differential
diagnosis in PMR [10,12,13], administration of TNF-a
inhibitors has been a therapeutic success [14]. In PMR,
however, no effect of the TNF-a antagonist infliximab
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recent randomized controlled trial (RCT) of newly diag-
n o s e dp a t i e n t s[ 1 5 ] .S t i l l ,i ts h o u l db en o t e dt h a ts e v e n
clinics participated in that study [15]. It can be expected
that a high number of clinics and doctors involved
increases the variation associated with clinical evaluation
and decisions concerning patients and, accordingly,
decreases the ability to detect differences between treat-
ment with TNF-a blockade and placebo. Furthermore, in
the mentioned RCT, patients had successfully been treated
with prednisone for some weeks before the start of inflixi-
mab therapy, which was applied in parallel with a fixed
tapering of prednisone treatment [15]. If at all stages the
scheduled prednisone dose per se would be sufficient to
control the disease, this may have hampered the ability of
the study to detect any potential beneficial effect of the
added TNF-a blockade.
Finally, even if infliximab has no effect in patients with
PMR, the TNF-a antagonist etanercept might still be
effective, because the two TNF-a inhibitors act by dif-
ferent mechanisms, being an anti-TNF-a monoclonal
antibody and a soluble recombinant Fc-coupled TNF-a
receptor fusion protein, respectively. Correspondingly,
infliximab and etanercept have different therapeutic
potentials in other diseases, for example, only infliximab
is effective in granulomatosis disorders such as Crohn’s
disease and Wegener’s granulomatosis [16]. Also, small
uncontrolled studies have pointed to a beneficial effect
of etanercept in patients with PMR [17,18]. Moreover,
in a RCT of patients with giant cell arteritis (GCA),
which is intimately related to PMR, etanercept was
shown to be an effective therapy [19].
As there is a need for effective drugs other than GCs
for PMR, and because existing evidence does not
exclude a role of etanercept, in the present study we
performed the first RCT of etanercept in patients with
PMR. The study was a parallel group in a placebo-
controlled, double-blinded, RCT with etanercept in a
group of newly diagnosed, GC naïve PMR patients and
non-PMR control subjects. The trial was carried out at
as i n g l ec e n t e r ,a n da l lp a t i e n t sw e r ed i a g n o s e da n d
evaluated by the same chief rheumatologist. Further-
more, etanercept was the only anti-inflammatory drug
administered. So, the study allows evaluation of the
pure effect of etanercept treatment in patients with
P M Rw i t h o u ta n yp o s s i b l eb l u r r i n gi n t e r f e r e n c ed u et o ,
for example GC treatment. The duration of the trial
was 14 days, because for etanercept to be an attractive
alternative to GCs in the treatment of patients with
PMR, beneficial effects must occur rapidly. Rapid
action of an effective anti-TNF-a therapy can also be
expected, if TNF-a does in fact play a key role in the
pathophysiology of PMR. In agreement with this view,
in RA a clear effect of TNF-a antagonism can be
expected within a week [20].
Materials and methods
Participants
Patients with suspected PMR were recruited by referral
from general practitioners in the Copenhagen municipal
area from July 2007 to May 2009. Non-PMR control
subjects were recruited by newspaper advertising during
the same period. Patients were eligible if they had been
diagnosed with PMR according to the Chuang criteria
[21], and if they did not fulfill the exclusion criteria,
which were: prior or current use of GCs or other immu-
nosuppressive drugs; signs of GCA including cranial
symptoms of vasculitis (headache, visual disturbances,
jaw claudication, abnormal pulsation or wall of temporal
artery, scalp tenderness); infections with systemic
impact; hepatitis B or C infection; positive tuberculosis
screening tests (thorax x-ray imaging, Mantoux skin test
and Quantiferon tuberculosis blood test); positive blood
or urine culture; uncontrolled diabetes mellitus; uncon-
trolled hypertension; severe heart failure (New York
Heart Association class 3 and 4); other inflammatory
diseases than PMR; cancer in the past five years; neuro-
muscular disease; thyroid disease; disturbance of calcium
homeostatis. Control subjects fulfilled the same exclu-
sion criteria as patients and were matched according to
sex, age, and body mass index (BMI). Withdrawal cri-
teria were non-compliance, serious exacerbation of the
disease, development of serious infections, development
of heart failure, and other suspected unexpected serious
adverse reactions.
Concurrent use of nonsteroidal anti-inflammatory
drugs and GCs was not allowed in both patients and
control subjects. One hundred 50 mg tablets of the cen-
trally active opioid-like analgesic tramadol (Mandolgin,
Sandoz A/S, Odense, Denmark) were given to the
patients, who were instructed to administer them in
order to adequately control pain symptoms during the
trial (no more than eight tablets per day); patients regis-
tered their use of tramadol using a standardized form
during the entire trial.
Trial design
The study was conducted at the Department of Rheu-
matology at Bispebjerg Hospital, Copenhagen, Denmark
as a 14-day single-center, double-blinded, prospective
RCT, comparing the effect of 14 days of etanercept
treatment (n = 10) against 14 days of placebo treatment
(n = 10) in a group of 20 patients with PMR and in an
equal sized group of matched control subjects.
The trial was approved by the Danish Medicines
Agency (approval number 2612-3497), the Ethical
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ber H-D-2007-0040), and by the Danish Data Protection
Agency. Furthermore, the trial was entered in the
European Eudract database (Eudract number 2007-
003009-28), and it was registered in the public database
clinicaltrials.gov (trial identifier NCT00524381). The
study was conducted according to the International
Conference on Harmonisation of Good Clinical Prac-
tices and was monitored by a good clinical practice
monitoring unit before, during, and after the trial per-
iod. At the time of screening for trial inclusion, potential
participants received thorough written and oral informa-
tion of the purpose and duration of the trial as well as
of predictable adverse events. Before inclusion in the
study, all participants signed a written informed consent.
Randomization and blinding
Following enrollment by a rheumatology specialist (the
senior author), participants were randomly assigned to
treatment with etanercept or placebo in a 1:1 ratio.
A five-block randomization scheme was generated
using the web site Randomization.com[22] by two trial-
associated senior nurses, who were also responsible for
drug preparation and who had no contact with the par-
ticipants. When included in the trial, subjects were con-
secutively assigned an identification number according
to the randomization scheme by the same two nurses.
Subjects who withdrew from the trial were consecutively
replaced by new subjects and allocated to the same
treatment. Physicians and technicians in direct contact
with participants or those responsible for data and
plasma analysis including staff that administered the
medication were blinded to group assignment. The
blinding code was not broken until all trial outcomes
had been collected.
Examinations
One to three days after inclusion in the study, subjects
were examined the first of two times, 14 days apart.
They were brought by taxi to the laboratory after an
overnight fast including abstinence from alcohol and
tobacco. Subjects were allowed to take their usual
medication, if any, in the morning before the examina-
tion but abstained from analgesics. A cannula was
inserted into a forearm vein, and subjects rested in a
chair 15 minutes before blood samples were drawn. A
clinical examination focusing on joint mobility and
muscle tenderness was carried out, and a health assess-
ment questionnaire (HAQ; evaluated for use in RA
[23]) and some supplementary questions about morn-
ing stiffness and daily physical activity were answered.
At the end of the first examination, subjects had their
first of four injections with trial medication. The last
injection was given three days before the final exami-
nation (end of study).
Interventions
Etanercept (Enbrel, Wyeth Pharmaceuticals New Lane,
Hampshire, UK) was injected subcutaneously biweekly
i nt h et h i g ha tt h es t a n d a r dd o s eo f2 5m g( 1m l ) .
Placebo was 1 ml isotonic saline. Individual injections
were given at least 3 cm apart. To ensure proper blind-
ing, etanercept and placebo, which were both colorless
solutions, were prepared in indistinguishable syringes by
nurses, who had no interaction with the subjects.
Study outcomes
T h ep r i m a r yo u t c o m ew a st h ec h a n g ei nP M Ra c t i v i t y
score (PMR-AS [24-26]), from baseline to end of study
(day 15) in patients and control subjects treated with eta-
nercept or placebo. PMR-AS was calculated from mea-
surements of plasma CRP levels (mg/dl), the duration of
morning stiffness (MST, minutes), the ability to raise the
arms (E, 3 to 0: 3 = no elevation possible; 2 = elevation
possible below shoulder height; 1 = elevation possible
above shoulder height; 0 = full elevation possible), physi-
cian’s global assessment (physician’s visual analog scale
(VASph); 0 to 10 cm), and the patients’ assessment of pain
(patient’s visual analog scale (VASp); 0 to 10 cm), as [24]:
PMR AS CRP mg dl E 3 MST min 1 VAS  to 1  cm −= () +− () + () × () + () + /. 00 0 0 ph V VAS
 to 1  cm
p
00 () .
Secondary outcomes were: changes in ESR, cumulative
intake of tramadol during the study, and plasma TNF-a
and IL-6 concentrations in all groups at baseline and at
the end of the study (day 15). After treatment in
patients receiving etanercept, TNF-a concentrations
were also measured in immunoglobulin (Ig) G depleted
plasma. In patients, functional status was assessed before
and after etanercept treatment using the HAQ [23].
To ensure high accuracy of outcome assessments and
measurements, all participating staff carefully reviewed
the study protocol prior to the start of the trial. More-
over, standard operation protocols were used during all
trial-related activities.
Safety and adverse events
Assessment of the subjects’ safety included registration
of all adverse events as well as careful examination and
questioning of subjects before each injection and/or
examination.
Plasma samples
Blood samples were drawn in stock Vacutainers (Becton
Dickinson, Brpndby, Denmark) with EDTA anticoagu-
lant and the proteolysis inhibitor Trasylol (Bayer AG,
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fugation at 1,200 rpm at 4°C for 15 minutes and imme-
diately frozen at -80°C until analysis.
Analytical methods
ESR and blood CRP were measured at an ISO-certified
(ISO 15189:2008) clinical laboratory using the Wester-
gen method (Becton Dickinson, BD Sedi-15) and colori-
metric slide tests (measurement range: 5 to 90 mg/l;
intra- and interassay coefficients of variation (CV): 2.2%
and 10.0%, respectively), respectively. Plasma TNF-a
and IL-6 were analyzed using the Luminex 100 platform
(Ramcon, Birkeroed, Denmark); specific kits used were
Milliplex (Millipore, ElectraBox Aps, Roedovre, Den-
mark). Detection levels and intra- and interassay CVs
were: TNF-a 0.05 pg/ml, 3.5% and 3.8%, respectively;
IL-6 0.79 pg/ml, 13.6% and 13.3%, respectively. Analyses
were carried out on unprocessed plasma. Furthermore,
TNF-a was also determined in plasma processed by
protein G-based spin columns (Albumin and IgG Deple-
tion Spin Trap, GE Healthcare, Uppsala, Sweden), which
remove IgGs including free etanercept and etanercept-
TNF-a complexes. To compensate for loss in the
columns of free TNF-a and of proteins influencing stan-
dard curves, standards dissolved in plasma analogue
(matrix included in the MilliPlex kit) were also passed
through the spin columns.
Statistics
We estimated the sample size based on an effect size on
PMR-AS of r =| 0 . 7 5 | .T h u s ,a ta na-level of 0.05 and
at a statistical power of 80% (in two-tailed testing), the
m i n i m u ms a m p l es i z es h o u l db en i n es u b j e c t si ne a c h
treatment arm.
Statistical analysis was performed using SPSS 17.0.1
for Mac (SPSS Inc., Chicago, IL, USA). Unless otherwise
stated, data are mean ± standard error of the mean. A
two-way analysis of variance was used to determine if
data differed between patients and control subjects, if
changes occurred with treatment, and if there was any
interaction between group and treatment. P-values
below 0.05 in two-tailed testing were considered
significant.
Results
Twenty-two patients with PMR were included in the
trial; of these, two patients, both receiving placebo, with-
drew from the study (Figure 1). Twenty-one control
subjects without PMR were included; one control sub-
ject receiving etanercept withdrew (Figure 1). Baseline
anthropometric and clinical findings did not differ (P >
0.05) between patients who received etanercept and
patients who received placebo (Figures 2 and 3, and
Table 1). Nor did these variables differ between control
subjects receiving etanercept and placebo, respectively
(Table 2, P >0 . 0 5 ) .A g e ,B M I ,a n db l o o dp r e s s u r ed i d
not differ (P > 0.05) between patients and control sub-
jects; before treatment all other measurements differed
significantly (P < 0.001 to 0.01) between these groups
(Tables 1 and 2, and Figure 3).
After the 14 days of trial participation, all patients
were treated with 20 mg/day prednisolone. Within a
week, prednisolone abolished any remaining PMR symp-
toms and normalized CRP and ESR in all patients, sup-
porting the PMR diagnosis.
Primary outcome: PMR-AS
At baseline, PMR-AS did not differ between patients
treated with etanercept and patients treated with pla-
cebo (Figure 2, P > 0.05); it was, however, significantly
higher in patients than in control subjects (Figure 2, P <
0.0001 to 0.01). In all control subjects, PMR-AS did not
differ significantly from zero (Figure 2, P > 0.05).
During the 14 days of etanercept treatment, PMR-AS
significantly decreased by 24% (95% confidence interval:
12 to 33%) in patients (Figure 2), but remained signifi-
cantly higher in patients compared with control subjects
(Figure 2, P < 0.0001 to 0.01). In patients receiving
placebo, PMR-AS did not change (P > 0.05).
Secondary outcomes
In patients with PMR, CRP, E and VASph decreased sig-
nificantly during etanercept treatment (Figure 3), whereas
during placebo treatment only CRP decreased and to a
lesser extent (P < 0.05; Figure 3). Also the other compo-
nents of the PMR-AS (MST and VASp)t e n d e dt o
decrease during etanercept treatment; however, the
changes were not statistically significant (Table 1,
P > 0.05). ESR (Figure 3) as well as IL-6 (Figure 4), which
at baseline were markedly higher in patients than in con-
trol subjects, decreased in PMR patients receiving etaner-
cept, but not (P > 0.05) in patients receiving placebo. The
cumulative intake of tramadol (Table 1) was 17% lower
in patients treated with etanercept compared with
placebo, but the difference was not significant (P > 0.05).
HAQ variables did not change in patients receiving eta-
nercept or placebo (data not shown). By the end of the
trial, the various variables still did not differ significantly
between patients receiving etanercept and placebo
(P > 0.05). However, the mean IL-6 concentration was
markedly higher in patients receiving placebo, and this
difference was of borderline significance (Figure 4).
Furthermore, all disease parameters were still signifi-
cantly higher compared with values in control subjects
(P < 0.05). In control subjects, no changes were seen
after either etanercept or placebo treatment.
At baseline, plasma TNF-a concentrations were signifi-
cantly higher in patients than in control subjects (Figure 5).
Kreiner and Galbo Arthritis Research & Therapy 2010, 12:R176
http://arthritis-research.com/content/12/5/R176
Page 4 of 9During etanercept treatment TNF-a concentrations mark-
edly increased in both groups (Figure 5). During placebo
treatment, TNF-a concentrations in plasma decreased in
patients but stayed constant in control subjects (Figure 5).
The high concentrations seen in patients treated with eta-
nercept were reduced by 61% (P = 0.02) by IgG depletion
of plasma, and became similar to concentrations in pla-
cebo-treated patients (values before vs after IgG depletion
in etanercept (n = 10) and placebo (n = 10) treated
patients, respectively: 16.9 ± 2.6 pg/ml vs 10.4 ± 1.3 pg/ml;
7.1 ± 0.7 pg/ml vs 11.5 ± 1.3 pg/ml).
Safety and adverse events
Generally, etanercept treatment was well tolerated in all
subjects. Two patients and one control subject, all trea-
ted with etanercept, had minor local injection-site reac-
tions (rashes). One control subject treated with placebo
reported an unsuspected feeling of fatigue. No suspected
unexpected serious adverse reactions were observed in
any of the subjects.
Discussion
The present study is the first RCT of the effect of eta-
nercept in patients with PMR. The major finding is that
14 days of etanercept monotherapy ameliorates disease
activity in newly diagnosed, GC-naïve patients with
PMR. However, the effect is modest indicating that
TNF-a does not have a predominant role in the patho-
physiology of PMR.
The positive effect of etanercept is evident from the 24%
reduction of PMR-AS in patients treated with the drug, as
well as the insignificant changes in PMR-AS observed in
placebo-treated patients (Figure 2). The reduction of
PMR-AS in patients treated with etanercept reflected
decreases in all paraclinical as well as objective and subjec-
tive clinical components of PMR-AS. Among these, statis-
tically significant improvements in shoulder mobility (E),
physician’s global assessment (VASph) and CRP were seen,
and these changes were paralleled by a significant decrease
in ESR and plasma IL-6 concentration (Figures 3 and 4).
The fact that both etanercept and placebo had no effect in
non-PMR control subjects (Figures 2 to 4, and Table 2)
shows that the significant effects of etanercept seen in
patients with PMR were indeed disease specific.
Figure 1 Flow of patients and controls through the trial. This includes randomization, withdrawal numbers and reasons, and number of
participants, who completed the study.
Figure 2 Primary outcome. Polymyalgia rheumatica activity score
(PMR-AS) in 20 patients with PMR and 20 non-PMR control subjects
at baseline (black bars) and after (white bars) 14 days of treatment
with etanercept or placebo. PMR-AS is calculated from the blood
level of C-reactive protein, duration of morning stiffness, subject’s
assessment of pain (visual analog score (VAS)), physician’s global
assessment (VAS), and the subject’s ability to elevate the arms (see
text). Δ all values in control subjects significantly different (P <
0.0001 to 0.01) from values in patients.
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modest in patients with PMR is suggested by the fact
that the reductions in both MST and VASp were not
statistically significant (Table 1). Furthermore, at the
end of the 14 days of etanercept treatment, PMR-AS
was still not only higher than in control subjects but
also not significantly different from values in placebo-
treated patients (Figure 2). Correspondingly, although
the tramadol intake was lower in etanercept compared
with placebo-treated patients, the difference was not
Figure 3 Clinical and paraclinical measurements in patients with polymyalgia rheumatica at baseline (black bars) and after (white
bars) 14 days of treatment with etanercept or placebo. C-reactive protein (CRP), patients’ ability to elevate the arms (E, 3 to 0: 3 = no
elevation possible; 2 = elevation possible below shoulder height; 1 = elevation possible above shoulder height; 0 = full elevation possible), the
physician’s global assessment (visual analog score, VAS), and erythrocyte sedimentation rate (ESR).
Table 1 Characteristics of patients at baseline and after etanercept/placebo treatment
Before etanercept
(n = 10)
Before
placebo
(n = 10)
After etanercept
(n = 10)
After
placebo
(n = 10)
Sex (female/male) 6/4 7/3 - -
Age (years) 72.6 ± 2.6 71.4 ± 3.6 - -
BMI (kg/m
2) 23.6 ± 3.4 24.9 ± 4.1 - -
Blood pressure
(systolic/diastolic, mmHg)
160 ± 5/87 ± 4 159 ± 4/87 ± 5 - -
Smokers (n) 23 - -
Hypertension (n) 63 - -
Hypercholesterolemia (n) 32 - -
Physical activity level
before PMR onset
(1, high; 2, medium; 3, low)
1.4 ± 0.1 1.9 ± 0.2 - -
Physical activity level
(1, high; 2, medium; 3, low)
2.9 ± 0.1 2.9 ± 0.1 2.7 ± 0.2 3.0 ± 0
Morning stiffness (min) 98 ± 16 117 ± 19 70 ± 17 103 ± 21
Patients’ assessment of pain, VAS (0-10 cm) 6.2 ± 0.7 5.0 ± 0.8 5.9 ± 0.6 5.4 ± 0.5
Cumulative intake of tramadol (tablets/14 days) - - 47 ± 8 55 ± 12
Data are mean ± standard error of the mean. PMR, polymyalgia rheumatica; VAS, visual analog scale.
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by HAQ did not improve in any of the groups.
In order to verify that the anti-TNF-a treatment was still
effective at the final evaluation by day 15, that is, three
days after the last etanercept injection, and that potential
effects of the blockade accordingly were not underesti-
mated, plasma TNF-a concentrations were determined.
However, instead of being reduced, in etanercept-treated
patients the TNF-a concentrations were higher than
before treatment and also higher than in placebo-treated
patients (Figure 5). The increased TNF-a values observed
after etanercept treatment were probably due to the simul-
taneous detection of both free and accumulated etaner-
cept-bound TNF-a [27]. In agreement with this view,
during etanercept treatment of control subjects TNF-a
concentrations were also markedly increased (Figure 5).
Table 2 Characteristics of control subjects at baseline and after etanercept/placebo treatment
Before etanercept
(n = 10)
Before
placebo
(n = 10)
After etanercept
(n = 10)
After
placebo
(n = 10)
Sex (female/male) 9/1 6/4 - -
Age (years) 69.9 ± 1.2 77.0 ± 5.7 - -
BMI (kg/m
2) 25.5 ± 0.9 26.4 ± 1.4 - -
Blood pressure
(systolic/diastolic, mmHg)
148 ± 5/85 ± 3 150 ± 4/85 ± 2 - -
Smokers (n) 23 - -
Hypertension (n) 54 - -
Hypercholesterolemia (n) 21 - -
Physical activity level
(1, high; 2, medium; 3, low)
*1.5 ± 0.2 *1.9 ± 0.1 *1.6 ± 0.2 *1.8 ± 0.2
ESR (mm/hr) *11.0 ± 3.1 *9.1 ± 1.3 *9.4 ± 2.8 *13.5 ± 1.2
CRP (mg/dl) *1.1 ± 0.1 * < 1.0 * < 1.0 * < 1.0
Elevation of arms (3-0) *0 *0 *0 *0
Morning stiffness (min) *6.0 ± 2.0 *0 *0 *0
Physician’s global assessment, VAS (0-10 cm) *0.2 ± 0.2 *0 *0 *0
Subjects’ assessment of pain, VAS (0-10 cm) *0.75 ± 0.5 *1.0 ± 0.4 *0.06 ± 0.1 *0
Data are mean ± standard error of the mean.
CRP, C-reactive protein; ESR, erythrocyte sedimendation rate; VAS, visual analog scale.
*Values significantly different from values in patients with polymyalgia rheumatica (P < 0.001 to 0.01).
Figure 4 Plasma IL-6 concentrations in patients with
polymyalgia rheumatica (PMR) and non-PMR control subjects at
baseline (black bars) and after (white bars) 14 days of treatment
with etanercept or placebo. Δ all values in control subjects
significantly different (P < 0.01 to 0.001) from values in patients.
Figure 5 Plasma TNF-a concentrations in patients with
polymyalgia rheumatica (PMR) and non-PMR control subjects
at baseline (black bars) and after (white bars) 14 days of
treatment with etanercept or placebo.
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a concentrations were reduced by 61% after IgG deple-
tion of plasma. This process also removes etanercept
(free etanercept as well as etanercept-TNF-a com-
plexes), which contains the Fc fragment of IgG1. TNF-a
concentrations were similar in IgG-depleted plasma
from etanercept-treated compared with placebo-treated
patients. As some etanercept-bound TNF-a will remain
in IgG-depleted plasma from etanercept-treated patients,
while only free TNF-a is present in IgG-depleted plasma
from placebo-treated patients, the similar overall TNF-a
concentrations in IgG-depleted plasma most likely
r e f l e c tt h a tf r e eT N F - a concentrations were lower in
plasma from etanercept-treated patients than in plasma
from placebo-treated patients. So, these observations
indicate that by the end of the trial, etanercept was still
present in plasma and able to lower free TNF-a concen-
trations compared with values in placebo-treated
patients [27].
In the present study, TNF-a concentrations in plasma
were higher in patients with PMR than in non-PMR
controls subjects (Figure 2) before treatment in both
treatment groups. This is in accordance with findings in
a recent study, in which we showed that interstitial
TNF-a concentrations in affected muscle are increased
in untreated PMR and normalized in parallel with com-
plete clinical remission during 14 days of prednisolone
therapy [9]. Although these findings are suggestive, the
fact that in the present study TNF-a blockade had only
a modest limiting effect on disease activity indicates that
TNF-a is not a major determinant of the pathophysiol-
o g yi nP M R .I n t e r e s t i n g l y ,i nas t u d yo ft w op a t i e n t s
with previously untreated GCA, a condition generally
considered to be closely related to PMR, a dramatic
improvement was observed within 14 days of monother-
apy with the anti-TNF-a monoclonal antibody inflixi-
mab, and it was concluded that in this disease TNF-a
plays a major role in mediating inflammation [28].
In the present study, the same experienced rheuma-
tology specialist evaluated all patients. It is interesting
to note that although being blinded to treatment alloca-
tion, the specialist’s evaluation of disease activity as
reflected by shoulder mobility (E) and VASph,w a si n
better agreement with paraclinical measures (ESR, CRP,
and IL-6) than the patients’ own evaluations of disease
activity as apparent from MST, VASp,a n dH A Q .D u e
to the monotherapeutic design of the present RCT,
potential effects of etanercept were not obscured by
simultaneous administration of other anti-inflammatory
drugs such as GCs. As a consequence, however, the
trial had to be brief. Thus, it is possible that a larger
effect of etanercept would have been demonstrated had
it been possible to extend the duration of the trial.
However, in patients with RA the effect of etanercept
occurs rapidly [20]. Furthermore, in patients with GCA
a small uncontrolled study showed a dramatic effect of
infliximab monotherapy treatment in the early phase
[28]. Conversely, a RCT has shown that extension of
infliximab therapy to 22 weeks does not diminish the
need for simultaneous GC therapy [29]. Still, in some
contrast to the latter study, a GC-sparing effect of eta-
nercept has been demonstrated in a recent RCT when
administered late in the course of GCA in patients with
side effects from GC [19]. However, such patients may
have a particularly strong inflammatory reaction making
them relatively GC-resistant [6,30] and sensitive to
TNF-a blockade [31].
The disease ameliorating effect of etanercept seen in
the present study contrasts with the lack of benefit of
infliximab found in a RCT with GC-treated, newly diag-
nosed patients with PMR [15]. This discrepancy may
reflect differences in study design or differences in
mechanism of action of the two TNF-a antagonists.
Arguing in favor of the latter possibility, in a small,
uncontrolled study, it was demonstrated that etanercept
was beneficial in the treatment of GC-treated patients
with newly diagnosed PMR and decompensated diabetes
[18]. However, arguing against the latter possibility, in
line with our findings, infliximab monotherapy induced
remission in a small, uncontrolled study with newly
diagnosed patients with PMR [17]. Moreover, in another
uncontrolled study of a small number of patients with
longstanding, GC-resistant PMR, administration of
infliximab was accompanied by diminished disease activ-
ity [32].
Overall, current evidence indicates that the effect of
TNF-a blockade in PMR and GCA is moderate. For
that reason and considering the high cost, TNF-a ther-
apy in PMR and GCA seems justified solely when these
diseases can only be controlled by GC doses that are
untenable due to serious adverse effects and comorbid-
ities induced or worsened by steroids.
Conclusions
In conclusion, the present RCT has demonstrated that
etanercept monotherapy ameliorates disease activity in
newly diagnosed, GC-naïve patients with PMR. How-
ever, the effect is modest, indicating that TNF-a does
not play a central role in the pathophysiology of PMR.
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